Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
PHJ Slootbeek, SH Tolmeijer, N Mehra… - Critical Reviews in …, 2024 - Taylor & Francis
The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been
fundamentally transformed by our greater understanding of its complex biological …
fundamentally transformed by our greater understanding of its complex biological …
Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer
Simple Summary Historically, the treatment of prostate cancer was a blanket approach for
all. Prostate cancer has not benefitted from targeted treatments based on specific tumour …
all. Prostate cancer has not benefitted from targeted treatments based on specific tumour …
Implementation of a telehealth genetic testing station to deliver germline testing for men with prostate cancer
PURPOSE: Germline testing for men with prostate cancer (PCa) poses numerous
implementation barriers. Alternative models of care delivery are emerging, but …
implementation barriers. Alternative models of care delivery are emerging, but …
[HTML][HTML] Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review
New classification systems based on molecular features have been introduced to improve
precision medicine for prostate cancer (PCa). This review covers the increasing risk of PCa …
precision medicine for prostate cancer (PCa). This review covers the increasing risk of PCa …
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
Background Multiple therapies exist for patients with metastatic castration-resistant prostate
cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains …
cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains …
PARP inhibition in prostate cancer with homologous recombination repair alterations
A von Werdt, L Brandt, OD Schärer… - JCO Precision …, 2021 - ascopubs.org
PURPOSE With the broad use of next-generation sequencing assays, it has become clear
that mutations in DNA repair genes are more commonly found than previously reported. In …
that mutations in DNA repair genes are more commonly found than previously reported. In …
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations
Background Among men with metastatic prostate cancer, about 10% have germline
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …
alterations in DNA damage response genes. Most studies have examined BRCA2 alone or …
Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: a white paper from the Germline Genetics Working Group of …
Purpose Advances in germline genetics, and related therapeutic opportunities, present new
opportunities and challenges in prostate cancer. The Prostate Cancer Clinical Trials …
opportunities and challenges in prostate cancer. The Prostate Cancer Clinical Trials …
Clinical implications of genomic alterations in metastatic prostate cancer
There has been a rapid expansion in treatment options for the management of metastatic
prostate cancer, but individual patient outcomes can be variable due to inter-patient tumor …
prostate cancer, but individual patient outcomes can be variable due to inter-patient tumor …
SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)
J Cassinello, JÁ Arranz, JM Piulats, A Sánchez… - Clinical and …, 2018 - Springer
Androgen deprivation treatment was the only treatment available for metastatic prostate
cancer until recently, with docetaxel as the only treatment with a proven survival benefit in …
cancer until recently, with docetaxel as the only treatment with a proven survival benefit in …